首页> 外国专利> 9-Oxo-11-alpha methyl prosta-13-enoic acid derivs - as selective anti-ulcer agents without hypotensive or intestinal-contracting side effects

9-Oxo-11-alpha methyl prosta-13-enoic acid derivs - as selective anti-ulcer agents without hypotensive or intestinal-contracting side effects

机译:9-Oxo-11-alpha甲基prosta-13-烯酸衍生-作为选择性抗溃疡药,无降压或肠收缩性副作用

摘要

Prostenoic acid derivs. of formula (I) and their pharmaceutically acceptable salts are new: (where A = 4-8 C alkylene, esp. hexamethylene; R1 = 1-5C alkyl, esp. n-propyl; R2 and R3 are H or 1-4 C alkyl; R4 = H or 1-4 C alkyl). They are prepd. from corresp. 9-(protected oxo)-15-oxo cpd. by redn. then deprotection. (I) are anti-ulcer agents with little or no hypotensive or intestinal-contracting side effects. Thus, in the rat, 9-oxo-11 alpha 16, 16-trimethyl-15 alpha-hydroxyprost-13-trans-enoic acid has ED50 against indomethacin-(30 mg./kg.) induced ulcer of 0.16 mg./kg. Usual dose is 0.5-100 mg./day for adults e.g., as 3-4 tablets.
机译:脯氨酸衍生。 (I)的式(I)及其药学上可接受的盐是新的:(其中A = 4-8 C亚烷基,尤其是六亚甲基; R1 = 1-5C烷基,特别是正丙基; R2和R3是H或1-4 C烷基; R 4 = H或1-4个碳的烷基)。他们准备好了。来自corresp。 9-(保护的氧代)-15-氧代cpd。通过重做。然后解除保护。 (I)是抗溃疡药,几乎没有或没有降压或肠收缩的副作用。因此,在大鼠中,9-oxo-11 alpha 16、16-trimethyl-15α-hydroxyprost-13-trans-enoicacid对吲哚美辛-(30 mg./kg。)诱发的溃疡的ED50为0.16 mg./kg 。成人的常规剂量为0.5-100毫克/天,例如3-4片。

著录项

  • 公开/公告号FR2346003A1

    专利类型

  • 公开/公告日1977-10-28

    原文格式PDF

  • 申请/专利权人 SANKYO CY LTD;

    申请/专利号FR19750016321

  • 发明设计人

    申请日1975-05-26

  • 分类号A61K31/19;C07C177/00;

  • 国家 FR

  • 入库时间 2022-08-22 23:44:40

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号